News

The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

Vertex Receives FDA Acceptance for Povetacicept Application in IgA Nephropathy

Tuesday, June 02, 2026

Vertex Pharmaceuticals has announced that the US Food and Drug Administration FDA has accepted its Biologics License Application BLA for povetacicept an investigational treatment for adults with immunoglobulin A nephropathy IgAN

FDA Grants Breakthrough Therapy Status to Merck’s Calderasib for KRAS G12C-Mutated NSCLC

Saturday, May 30, 2026

Merck known as MSD outside the United States and Canada has received Breakthrough Therapy designation from the US Food and Drug Administration FDA for calderasib MK an investigational oral KRAS GC inhibitor

Innovent Biologics and Pfizer form global partnership for oncology drug development

Friday, May 29, 2026

Innovent Biologics and Pfizer have entered into a global strategic collaboration to develop earlystage and newly discovered cancer medicines The agreement covers the research and development of antibodydrug conjugates

Alzprotect receives FDA clearance for AZP2006 trial in PSP

Thursday, May 28, 2026

Alzprotect has received clearance from the US Food and Drug Administration for its Investigational New Drug IND application for AZP Ezeprogind to treat Progressive Supranuclear Palsy PSP

CordenPharma to Acquire AmbioPharm to Expand Global Peptide API Capacity

Wednesday, May 27, 2026

CordenPharma has announced an agreement to acquire AmbioPharm a USbased peptide active pharmaceutical ingredient API contract development and manufacturing organisation CDMO

Engage Bio Acquired by Lilly to Support Development of Non-Viral Genetic Medicines

Thursday, May 21, 2026

Engage Biologics Inc a preclinical biotechnology company focused on nonviral DNA delivery has been acquired by Eli Lilly and Company

Hansa Biopharma signs €115 million IDEFIRIX licensing agreement with SERB Pharmaceuticals

Wednesday, May 20, 2026

Hansa Biopharma has entered into an exclusive licensing agreement worth million with SERB Pharmaceuticals for the development and commercialisation of IDEFIRIX imlifidase across Europe and the Middle East and North Africa MENA region

Regeneron and Parabilis Medicines Partner to Develop Novel Antibody-Helicon Therapies

Tuesday, May 19, 2026

Regeneron Pharmaceuticals has entered into a strategic research collaboration with Parabilis Medicines to develop multiple therapeutic candidates based on Parabilis Helicon peptide platform with a focus on AntibodyHelicon Conjugates AHCs

INmune Bio receives FDA Fast Track designation for XPro1595 in early Alzheimer’s disease

Friday, May 15, 2026

INmune Bio Inc has announced that the US Food and Drug Administration has granted Fast Track designation to XPro pegipanermin for the treatment of early Alzheimers disease

U.S. FDA Approves INQOVI® Plus Venetoclax for Acute Myeloid Leukaemia

Thursday, May 14, 2026

Taiho Oncology and Taiho Pharmaceutical have received approval from the US Food and Drug Administration for INQOVI decitabine and cedazuridine in combination with venetoclax for the treatment